Investigation into the Cima Universidad de Navarra, awarded at the National Congress of Medicine

investigation above And University of Navarre Clinic Awarded to The best work presented at the National Congress of the Spanish Society of Hematology and Hematology (SEHH), held in Pamplona

The development of multiple myeloma treatment is remarkable, but advances in tools that guide personalized treatments based on a patient’s risk are necessary. In this study, we identify the most relevant prognostic biomarkers in patients with newly diagnosed multiple myeloma. Dr.. Juan Jose Garces, a researcher in the multiple myeloma group in Sima and first author of the work, performed within the Hispanic Myeloma/PETHEMA group.

Featured for the third year

This is the third edition of the conference in which a team of researchers from University of Navarra They received the SEHH Best Work Award. “Two years ago, Goicoechea . River demonstrated the role of minimal residual disease studies in determining prognosis and understanding resistance mechanisms in patients with high-risk multiple myeloma.

last year, Catarina da Silva Unravel the clinical and biological significance of dysplastic changes in patients with multiple myeloma at diagnosis,” he recalls. Dr. Bruno Paiva, Co-Director of the Group and Research Member of CIBER de Cáncer (CIBERONC).